Physician profile
Christopher N Ta
NPI 1609903020
$18,317.54
in general payments reported to CMS, 2019-2025
14 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,955 · 2020: $1,715 · 2021: $722 · 2022: $5,526 · 2023: $531 · 2024: $428 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $999.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $6,283.59 | 2019-2022 | |
| Shire North American Group INC | $4,306.04 | 2019 | |
| Dompe Farmaceutici S.P.A. | $2,409.76 | 2025 | |
| Seagen INC. | $1,680.00 | 2020 | |
| Alcon Vision LLC | $1,190.05 | 2019-2025 | Clareon, Argos |
| Amgen INC. | $1,125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $499.47 | 2019-2022 | |
| Dompe US, INC. | $236.38 | 2022-2024 | Oxervate |
| Oyster Point Pharma, INC. | $217.52 | 2022-2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $162.43 | 2021 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2023 | Acthar |
| Biotissue Holdings INC. | $71.94 | 2021-2022 | |
| Genzyme Corporation | $35.37 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.